Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

SMS Pharmaceuticals Limited

SMSPHARMA · NSE · Healthcare · As of 4 Nov 2026Delayed / Sandbox EOD Data

₹525.50

+₹11.35 (+2.21%)(1D)

₹270.1052 Week Range₹535.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

66/100

Valuation

52/100

Quality

53/100

Growth

71/100

Health

78/100

Momentum

89/100

Valuation
52
Quality
53
Growth
71
Health
78
Momentum
89

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

SMS Pharmaceuticals Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹525.5

Market cap

₹4,920 Cr

P/E ratio

42.07

P/B ratio

6.26

Dividend yield

Not available

ROE

Not available

RSI 14

70.32

1Y return

Not available

SMS Pharmaceuticals Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the SMS Pharmaceuticals Limited (SMSPHARMA) stock page cover?

SMS Pharmaceuticals Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for SMSPHARMA?

SMS Pharmaceuticals Limited is currently shown with a delayed price near ₹525.5, P/E 42.07.

Does the SMSPHARMA page provide investment advice?

No. The SMSPHARMA page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

SENORES

Senores Pharmaceuticals Limited · Healthcare

SANOFI

Sanofi India Limited · Healthcare

SANOFICONR

Sanofi Consumer Healthcare India Limited · Healthcare

How to Use Anvest Intelligence Effectively: 10 Practical AI Stock Research Prompts

Master AI-assisted stock research on Indian equities. Learn how to construct grounded financial queries, audit concall guidance, verify filing citations, and avoid ungrounded AI hallucinations.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

The company's revenue is diversified across therapeutic areas such as Anti-diabetic, Anti Retro Viral (ARV), Anti-inflammatory, and others. Geographically, sales are generated from Europe, Asia (excluding India), North America, and India, with a notable presence in EOU/SEZ/DE.

Drug Manufacturers - GeneralFounded:1987CEO/MD:P. V. Ramana ReddyHQ:Hyderabad, Telangana

Business profile as of 2026-08-25

Revenue growth: +13.3%FY26 growth+19.3%3Y CAGR
EPS growth: +36.6%FY26 growthN/M3Y CAGR
CFO / PAT: 0.58×FY26

What Looks Strong

GrowthRevenue grew at +19.3% CAGR over three years.
MarketShareholder returns of +31.5% CAGR over five years.
Balance SheetConservative capital structure with manageable leverage of 0.46× Debt/Equity.

What to Watch

No material watchpoint identified from currently verified evidence.

Reports a single operating segment in its results filings.

FY26 (consolidated): revenue ₹887 cr, up 13% from ₹783 cr in FY25; net profit ₹102 cr, up 48% from ₹69.1 cr in FY25.
FY26 (consolidated): operating cash flow ₹59.2 cr (0.6× net profit); debt/equity 0.46×.
Latest quarter to Sep 2026 (consolidated): revenue ₹316 cr (up 30% year on year); net profit ₹39.9 cr.